Our concept.

SeqCure - specificity and potency combined.

Every human is unique, and so is every tumor. SeqCureNEO is a personalized cell therapy product, tailor-made from the mutation profile of each individual patient. From a blood sample, immune cells are isolated, stimulated, enriched, cultured - and returned to the patient. Our proprietary manufacturing process ensures that only the tumor-reactive cells are allowed to grow, thereby maintaining specificity and potency while minimizing side effects.

Key competitive features of SeqCureNEO


Highly individualized. The cell product is tailor-made from the mutation profile of each individual patient tumor.

Unprecedented level of control over tumor specificity, resulting in a cell product with high purity. The high purity enables delivery of the required dose to achieve a clinical response.

Whole blood (and not tumor tissue) is used as a source for the cell product, eliminating the need for additional surgical procedures.

SeqCureNEO is nonengineered and targets multiple neoantigens, ensuring high safety in combination with a much broader tumor reactivity compared to other cell immunotherapy products.

1. Sampling of blood and tumor tissue.

In order to identify tumor-driving mutations, small samples of blood and tumor are needed.
If tumor tissue samples have been stored from previous surgery and/or biopsy sampling, those samples may be used in this step, alleviating the need for additional invasive procedures.  

2. Deep sequencing.

From the blood- and tumor tissue samples, DNA and RNA are extracted and analysed using deep sequencing technology.

1. Sampling of blood and tumor tissue.

In order to identify tumor-driving mutations, small samples of blood and tumor are needed.
If tumor tissue samples have been stored from previous surgery and/or biopsy sampling, those samples may be used in this step, alleviating the need for additional invasive procedures.  

2. Deep sequencing.

From the blood- and tumor tissue samples, DNA and RNA are extracted and analysed using deep sequencing technology.

3. AI-powered bioinformatic analys and neoantigen prediction.

Using artificial intelligence-based bioinformatic algorithms, the patient's unique tumor-driving mutations are identified from the DNA- and RNA sequences analysed in the previous step.

4. Neoantigen synthesis.

Neoantigen peptides (small proteins) that correspond to the identified tumor-driving mutations are produced.

5. Cell expansion.

From a blood sample, immune cells are isolated and expanded in a cleanroom laboratory. During this phase, the cells are enriched and carefully monitored to ensure that potency as well as anti-tumor specificity is maintained throughout the culture.

6. Patient treatment.

Following purification and rinsing, the SeqCureNEO cell product is now ready to be administered to the patient. The transfer procedure is similar to an ordinary blood transfusion.

1. Sampling of blood and tumor tissue.

In order to identify tumor-driving mutations, small samples of blood and tumor are needed.
If tumor tissue samples have been stored from previous surgery and/or biopsy sampling, those samples may be used in this step, alleviating the need for additional invasive procedures.  

2. Deep sequencing.

From the blood- and tumor tissue samples, DNA and RNA are extracted and analysed using deep sequencing technology.

3. Bioinformatic analysis and neo-antigen prediction

Using advanced bioinformatic algorithms, tumor-driving mutations are identified from the DNA- and RNA sequences.

4. Peptide synthesis.

Neo-antigenic peptides (small proteins) that correspond to the identified tumor-driving mutations are produced.

5. Cell culture

From an additional small blood sample, immune cells are isolated and expanded in a clean room laboratory. During the cell expansion, the tumor-reactive cells grow in numbers from tens of thousands up to several billions. The previously synthesized neo-antigenic peptides are used during this step to ensure that the growing cells are stimulated to be reactive against the tumor.

6. Cell infusion

Following the expansion phase, the cells are purified and washed prior to transfer of the cell product to the patient. The transfer procedure is similar to an ordinary blood transfusion.